Ionis Pharmaceuticals (IONS) Income from Non-Controlling Interests (2009 - 2021)

Ionis Pharmaceuticals' Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at $500000.0 for Q4 2021.

• On a quarterly basis, Income from Non-Controlling Interests fell 98.56% year-over-year to $500000.0 in Q4 2021; TTM through Dec 2021 was $500000.0, a 66.67% increase from a year earlier, with the FY2025 full-year figure at $100000.0, changed 0.0% from the prior year.
• Income from Non-Controlling Interests eased to $500000.0 in Q4 2021 per IONS's latest filing, from $34.6 million in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $34.6 million in Q4 2020 and bottomed at -$17.3 million in Q4 2018.
• The 5-year median for Income from Non-Controlling Interests is -$9.1 million (2019), against an average of -$4.0 million.
• Across the five-year window, Income from Non-Controlling Interests surged 212.67% in 2019 and plunged 259.2% in 2020, its largest moves.
• Year by year, Income from Non-Controlling Interests stood at -$6.2 million in 2017, then tumbled by 177.64% to -$17.3 million in 2018, then jumped by 212.67% to $19.5 million in 2019, then jumped by 77.18% to $34.6 million in 2020, then plunged by 98.56% to $500000.0 in 2021.
• Per Business Quant, the three latest IONS Income from Non-Controlling Interests figures stand at $500000.0 (Q4 2021), $34.6 million (Q4 2020), and -$12.1 million (Q3 2020).